INCY
INCY clinical trials: INCYTE CORP
Every trial on ClinicalTrials.gov where INCYTE CORP is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 497
- Trials linked
- 308
- As lead sponsor
- 189
- As collaborator
- 6
- Primary completions as lead sponsor, next 90 days
INCY on the catalyst calendar · INCY registry changes
- Primary completion Mar 31, 2027Sponsor estimatePhase 1NCT07853040A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic ImpairmentIncyte Corporation · Hepatic InsufficiencyRecruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 14, 2029Sponsor estimatePhase 2NCT07823322A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer...Incyte Corporation · CRC (Colorectal Cancer)RecruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 12, 2027Sponsor estimatePhase 3NCT07214779Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With...Incyte Corporation · Ovarian CancerActive, not recruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 15, 2029Sponsor estimatePhase 3NCT07623200A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential ThrombocythemiaIncyte Corporation · Essential ThrombocythemiaRecruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 15, 2028Sponsor estimatePhase 3NCT07522073A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal...Incyte Corporation · Solid TumorsRecruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 24, 2030Sponsor estimatePhase 1NCT07441694Study of INCA036978 in Participants With Myeloproliferative NeoplasmsIncyte Corporation · Myeloproliferative NeoplasmsRecruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 25, 2028Sponsor estimatePhase 2NCT07213973Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaIncyte Corporation · Hidradenitis Suppurativa (HS)RecruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2029Sponsor estimatePhase 2NCT07124078A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at...Incyte Corporation · Chronic Graft-versus-host-diseaseRecruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 28, 2028Sponsor estimatePhase 3NCT06855498Rollover Study for Participants Previously Enrolled in Clinical Trials of PovorcitinibIncyte Corporation · Hidradenitis Suppurativa (HS)RecruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 28, 2027Sponsor estimatePhase 3NCT06585774A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseaseIncyte Corporation · Chronic Graft-versus-host-diseaseRecruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 28, 2026ActualPhase 3NCT06516965A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)Incyte Corporation · Prurigo NodularisActive, not recruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 1, 2028Sponsor estimatePhase 1/Phase 2NCT03934372Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid TumorsIncyte Biosciences International Sàrl · Acute Myeloid LeukemiaRecruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 29, 2026ActualPhase 3NCT06959225Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)Incyte Corporation · Hidradenitis SuppurativaActive, not recruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 1, 2026ActualPhase 3NCT06958211Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)Incyte Corporation · Hidradenitis SuppurativaActive, not recruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 15, 2026ActualPhase 1NCT07814404A Study to Assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB161734 in Healthy Male...Incyte Corporation · Healthy ParticipantsCompletedINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 29, 2028Sponsor estimatePhase 3NCT07284849A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line...Incyte Corporation · CRC (Colorectal Cancer)RecruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 23, 2027Sponsor estimatePhase 2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation · Immune ThrombocytopeniaRecruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 14, 2026Sponsor estimatePhase 1NCT07448155A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in...Incyte Corporation · Healthy ParticipantsActive, not recruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 17, 2031Sponsor estimatePhase 3NCT06615050A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in...Incyte Corporation · Graft-versus-host Disease (GVHD)RecruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 30, 2026ActualPhase 3NCT05429268Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large...Incyte Corporation · Large B-Cell LymphomaActive, not recruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 30, 2027Sponsor estimatePhase 2NCT05090891To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans ProgressivaIncyte Corporation · Fibrodysplasia Ossificans Progressiva (FOP)RecruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 25, 2031Sponsor estimatePhase 2NCT07862998A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable...Incyte Corporation · Unresectable CholangiocarcinomaNot yet recruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 28, 2026ActualPhase 2NCT05888844A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell CarcinomaIncyte Corporation · Cutaneous Squamous Cell CarcinomaTerminatedINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2026ActualPhase 2NCT05879822A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveIncyte Corporation · Advanced Solid TumorTerminatedINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2024ActualPhase 3NCT05764161A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)Incyte Corporation · Prurigo NodularisCompletedINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 472 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner